Survodutide
Also known as: Peptide-SU · BI 456906 · GLP-1/glucagon dual agonist
A dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim. Phase 2b trials showed superior weight loss to semaglutide at 6 months. Also being studied for NASH/MASH (metabolic steatohepatitis), a liver disease with limited treatment options.
What is Survodutide? A dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim. Phase 2b trials showed superior weight loss to semaglutide at 6 months. Also being studied for NASH/MASH (metabolic steatohepatitis), a liver disease with limited treatment options.
How does Survodutide work? Survodutide simultaneously activates GLP-1 receptors (appetite suppression, incretin effect) and glucagon receptors (increased energy expenditure, hepatic fat mobilization). The glucagon agonism component particularly drives liver fat reduction, making survodutide uniquely effective for metabolic liver disease in addition to obesity.
Benefits of Survodutide: Superior weight loss to semaglutide in Phase 2b (up to 19% at 46 weeks); Unique hepatic fat reduction via glucagon agonism (NASH/MASH); Once-weekly dosing; Both GLP-1 and glucagon receptor activation; Significant improvement in liver disease biomarkers; In Phase 3 trials for MASH and obesity
Survodutide dosage: Phase 2b dose range: 1.2-6.0mg/week. Titration recommended. Not yet FDA approved — Phase 3 trials ongoing as of 2025.
Research status: Clinical Trials
Source: PeptideWiki — https://www.peptide-wiki.net/peptides/survodutide
Mechanism of Action
Survodutide simultaneously activates GLP-1 receptors (appetite suppression, incretin effect) and glucagon receptors (increased energy expenditure, hepatic fat mobilization). The glucagon agonism component particularly drives liver fat reduction, making survodutide uniquely effective for metabolic liver disease in addition to obesity.
Benefits
- Superior weight loss to semaglutide in Phase 2b (up to 19% at 46 weeks)
- Unique hepatic fat reduction via glucagon agonism (NASH/MASH)
- Once-weekly dosing
- Both GLP-1 and glucagon receptor activation
- Significant improvement in liver disease biomarkers
- In Phase 3 trials for MASH and obesity
Side Effects & Risks
- Nausea and vomiting (GLP-1 class effects)
- Diarrhea
- Currently Phase 2/3 — long-term safety profile still being established
Where to Buy Survodutide
1 option across 1 vendor · Sorted cheapest first · All include direct product link
From
$99.99
All links are affiliate links — PeptideWiki earns a commission at no extra cost to you. Coupon codes apply at checkout. Prices and availability may change. Always verify COA before purchasing.
Storage & Reconstitution Guide
Storage Temperature
-20°C lyophilized, 4°C reconstituted
24 months (lyophilized), 28 days (reconstituted)
Reconstitution Solvent
Bacteriostatic water (BAC water)
Swirl gently — do not shake or vortex
Handling Notes
Protect lyophilized peptide from moisture and light. Once reconstituted, keep refrigerated. Discard if solution becomes cloudy or discolored. Use insulin syringe for precise dosing.
Step-by-Step Reconstitution
Gather supplies
BAC water, insulin syringe, alcohol swabs, vial
Disinfect tops
Swab rubber stoppers of both vials with alcohol
Draw BAC water
Pull desired mL of BAC water into syringe
Inject slowly
Inject BAC water down the side of the peptide vial, swirl gently to dissolve
Research Protocol
- Dose Range
- 1.2–4.8 mg
- Frequency
- Once weekly subcutaneous injection
- Cycle
- Ongoing / chronic
- Routes
- subcutaneous injection
- Notes
- Phase 2b dose range: 1.2-6.0mg/week. Titration recommended. Not yet FDA approved — Phase 3 trials ongoing as of 2025.
Legal & Regulatory Status
Sold for research purposes only. Not for human use. Laws vary by country.
Commonly Stacked With
View all peptide stacks →External Resources
Chemical Properties
- CAS Number
- 2059046-38-3
- Mol. Weight
- ~4,600 Da
PeptideWiki Research Team
Evidence-based research data sourced from PubMed and ClinicalTrials.gov · Last updated: February 25, 2026
Frequently Asked Questions About Survodutide
What is Survodutide?▾
A dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim. Phase 2b trials showed superior weight loss to semaglutide at 6 months. Also being studied for NASH/MASH (metabolic steatohepatitis), a liver disease with limited treatment options.
What are the benefits of Survodutide?▾
Superior weight loss to semaglutide in Phase 2b (up to 19% at 46 weeks)
What are the benefits of Survodutide?▾
Unique hepatic fat reduction via glucagon agonism (NASH/MASH)
What are the side effects of Survodutide?▾
Nausea and vomiting (GLP-1 class effects)
What is the recommended dosage for Survodutide?▾
Phase 2b dose range: 1.2-6.0mg/week. Titration recommended. Not yet FDA approved — Phase 3 trials ongoing as of 2025.
How long should a Survodutide cycle last?▾
Ongoing / chronic
More Weight Management Peptides
View all Weight Management peptides →5-Amino-1MQ
5-Amino-1-methylquinolinium
A small molecule inhibitor of NNMT enzyme that boosts metabolism and promotes fat cell apoptosis. Shows promise as a novel anti-obesity agent in preclinical research.
Retatrutide
LY3437943
An emerging triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show unprecedented weight loss of up to 24% body weight.
AOD-9604
AOD9604
A synthetic fragment of the C-terminus of HGH (amino acids 176-191) that retains the fat-burning properties of growth hormone without affecting blood sugar or IGF-1 levels.
MOTS-C
Mitochondrial Open Reading Frame of the 12S rRNA-c
A mitochondria-derived peptide that acts as a metabolic regulator, improving insulin sensitivity, exercise capacity, and potentially mimicking caloric restriction.